Today: 21 May 2026
Browse Category

NASDAQ:MFH 3 October 2025 - 6 October 2025

Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (MFH) Stock Skyrockets 1,400% in Crypto & AI Boom – Next Fintech Breakout or Bubble?

Mercurity Fintech Holding Inc. (NASDAQ: MFH) stock surged over 1,300% year-to-date in 2025, reaching an all-time high near $30 and a market cap close to $1.3 billion. The New York-based blockchain fintech shifted strategy to invest up to $500 million in crypto assets, backed by a $200 million Solana Ventures credit line. MFH joined the Russell 2000 and S&P Global indices this year. Full-year 2024 revenue was $1.01 million, with a $4.5 million net loss.
6 October 2025
···
Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Up 1,400% in a Year: Is Mercurity Fintech (MFH) the Next Crypto-Fintech Breakout or a Bubble?

Mercurity Fintech Holding (NASDAQ: MFH) stock has soared over 1,400% in the past year, reaching an all-time high near $30. The company pivoted to a $500 million crypto treasury strategy focused on Solana, securing a $200 million credit line from Solana Ventures after shelving a planned $43.7 million offering. MFH joined the Russell 2000 and S&P Global BMI in 2025. Despite this, 2024 revenue was just $1.01 million, with a $4.5 million net loss.
4 October 2025
····
Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (NASDAQ: MFH) surged about 1,320% year-to-date, trading near $28 on Oct 3, 2025, after starting 2024 near $1. The stock saw sharp swings, including a 27.6% drop Oct 1 and a 15.8% gain Oct 2. Recent moves include a $200M Solana venture line, gold asset tokenization deals, and index additions. Analyst consensus remains bearish, with a “Hold” rating and $4 price target.
3 October 2025
···

Stock Market Today

  • CyberTech Systems Earnings Raise Cash Flow Concerns Amid Market Stability
    May 20, 2026, 8:56 PM EDT. CyberTech Systems and Software Limited (NSE:CYBERTECH) posted earnings that met market expectations but revealed an accrual ratio of 0.53, indicating weaker free cash flow relative to profit. This financial metric, which measures non-cash earnings, signals potential challenges for upcoming profits as free cash flow of ₹76 million lagged behind reported profit of ₹304.3 million for the year ending March 2026. Despite a 28% annual growth in earnings per share (EPS) over three years, the decline in cash conversion may raise investor caution. The company's accrual ratio improved last year, suggesting the current shortfall could be temporary, but shareholders are advised to monitor cash flow trends closely against profitability for a clearer outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop